DIAMYD MEDICAL

”In the treatment of Diabetes and Diabetes related complications”



Extra General Shareholders meeting
March 10, 2008

Agenda

- 1. Opening of the meeting
- 2. Election of the Chairman Extra General Shareholder´s Meeting
- 3. Drawing up and approval of the voting list
- 4. Approval of the Agenda
- 5. Election of secretary and two persons to attest the minutes
- 6. Decision on proper notice of Extra General Meeting
- 7. The Board of Directors proposal of authorization and voting
- 8. Closing

About Diamyd Medical

- BioPharmaceutical company listed on NGM 1997
- Listed on OMX since 2002 (NOMX ticker: DIAM B)
- US ADR Level 1 since 2006 (ticker: DMYDY)
- Offices in Stockholm, Sweden & Pittsburgh, PA, USA

Autoimmune diabetes & Diabetes related complications

Diamyd® & NTDDS

Diamyd®

- GAD is a major antigen in the autoimmune attack against pancreatic beta cells that results in insulin dependent diabetes, also called autoimmune diabetes



- Diamyd Medical has an exclusively licensed patent portfolio which protects the therapeutic use of recombinant GAD

DIAMYD MEDICAL

Treatment with Diamyd®

- Small dose – 20 µg in 0.5 mL subcutaneous injection
- Two simple injections (day 1 and day 30)



- Significant effect for more than 30 months
- Clean safety profile

- Easy to administer, no hospitalization
- High acceptance among parents and patients

Diamyd® Clinical Trials to Date

- No treatment related Serious Adverse Events in any Diamyd® study!
- 149 patients treated with Diamyd® in total, of which 35 children
- Up to 5 yrs of follow-up



DIAMYD MEDICAL

Diamyd® Efficacy in Type 1 Diabetes

- Left: Patients with diabetes type 1 for less than 18 months
- Right: Patients with diabetes type 1 for less than 3 months





Received email (Swedish)

- Idag:
- Skiter jag i svenska "Jante"
- Ger jag tusan i att man inte ska "ropa hej förrän man är över bäcken"
- Bryr jag mig inte om att "man ska inte vara för glad för då..."
-
- Idag:
- Har jag facit på hand
- Vet jag att det ÄR alldeles på riktigt och sant
- att vår älskade Maria är en av 30 ungdomar i Sverige som har fått verksamt vaccin för diabetes
- att hon är en av fyra som kom in till sjukhuset i exakt rätt tid och gick in i diabetesstudien i exakt rätt stund och därmed är en av de som visar så gott resultat att det ser ut som om man har lyckats stoppa sjukdomsförloppet.
- Att hon idag efter tre långa ovissa år i en blindtest har ett medelvärde på sitt långtidsblodsocker på 4.
-
- Med innerlig värme och glädje böjer jag mig ödmjukt inför DIAMYD, svensk sjukvård, svensk forskning och den som varsamt vakade över Maria den dagen hon blev sjuk och en av deltagarna.
-
- Om framtiden vet man inget, hur långt vaccinet "bär henne" har vi ingen aning
- Men idag känns livet som en solig sommardag, på cykel i nedförsbacke och härlig medvind.
-
- *Med vänliga hälsningar*
- *Eva* *(Maria och Eva är fingerade namn)*

Worldwide recognition of Diamyd®

- ***Press Release, Stockholm, Sweden, November 22, 2007***

  "Diamyd Medical announced today that it has executed a Clinical Trial Agreement with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for a planned clinical study with the Diamyd® GAD-alum diabetes vaccine in 126 new onset type 1 diabetes patients..."

The study is conducted and sponsored by the NIH/NIDDK global network TrialNet, a group of the world's foremost experts and key opinion leaders in type 1 diabetes. The study is separate from the company's phase III program.

Current Status and Near-term Plans

- Start phase III trials during spring 2008
- 2 x 300 early onset T1D patients
- 0-3 months since diagnosis
- 15 month study period and 15 month follow-up

☑ US IND for phase III trials with Diamyd® filed in December 2007
– Principal Investigator: Professor Jerry Palmer, Seattle

Approval expected March 11<, 2008

☑ EU phase III trials with Diamyd® filed in Sweden in January 2008
– Principal Investigator: Professor Johnny Ludvigsson, Linköping

Approval expected March 18<, 2008

Diamyd® Applications

- Recent onset type 1 diabetes
- Preventive treatment of subjects with risk for developing type 1 diabetes
- Type 2-LADA
- Combination therapies with beta cell regeneration agents, e.g. GLP-1
- Use in beta cell transplantation
- Stem cell therapy



DIAMYD MEDICAL

Nerve Targeting Drug Delivery System (NTDDS)
New Class of Nerve Therapies

HSV Gene Delivery new class of nervous system disease therapies





- Intradermal delivery
  Vector taken up by neuron

- Therapeutic agent released into the synapse of the 1st order neuron and spinal cord

DIAMYD MEDICAL

NP2 – NTDDS+Enkephalin for Treatment of Chronic Pain

Preproenkephalin (PPE) is processed to form leu- and met-enkephalin opioid peptides. Binding to neuronal opioid receptors blunts pain signal generation.

Enkephalin peptides also have anti-inflammatory effects by acting on opioid receptors expressed on immune cells (eg. macrophages).



DIAMYD MEDICAL

Acute / Inflammatory Pain - Formalin Footpad Test

HSV Enkephalin Reduces Acute Pain



NP2 – Phase 1 Safety Trial – Cancer Pain

- Phase 1 Clinical study Q2 2008
  - Dose escalation trial with 12 patients in three dose cohorts
- IND approved February 2008
- University of Michigan – Principal Investigator David Fink, MD
- Localized pain from cancer. Pain rated very bad for 2 weeks prior to trial. Pain score and opioid use monitored
- Clinical GMP Manufacturing completed - COA issued

Product Pipeline

Project	Product	Lead Indication
AUTOIMMUNE DIABETES		
Diamyd®	GAD65	Type 1 New Onset
Diamyd®	GAD65	Type 2 - LADA
NEUROLOGY		
NP2	Enkephalin	Cancer Pain
NG2	GAD	SCI Diabetes Pain Neuropathic pain Shingles
Neurologix Inc (Licensed out)		Parkinson's disease
CANCER (license out)		
NC3	TNF alpha TK, Connexin	Glioma



DIAMYD MEDICAL

Proposal

- The Board of Directors proposal for authorization on one or several occasions before the next Annual Shareholders' Meeting, with or without consideration of the preferential shareholder rights to issue 91,000 shares of series B and warrants which will give the right to subscribe for 991,000 B-shares.

Proposal cont.

- The authorization is proposed to be valid for acquiring whole or parts of companies, assets, and cash or for settlements or other conditions as stated in chapter 2 §5 second paragraph 1-3 and 5 in the Companies Act.

Proposal cont.

- After full execution of the authorization of issuing shares in combination with the authorization given at the Annual Shareholders' Meeting, the dilution is calculated to 10 percent of the share capital, based on the total number of shares.
- After full execution of the authorization of the warrants and if they are fully subscribed, the dilution is calculated to additionally 10 percent.

Diamyd Investment History & Future



Over the years, the Company has had a modest cash burn, and shareholders have invested a total of approximately US$55M (SEK350M)

DIAMYD MEDICAL

Potential Roadmap – Current View

2008

Diamyd®
- Phase III studies in US and EU
- TrialNet intervention trial
- 5 year data from Phase IIa LADA trial
- Publication of 30 month results from Phase IIb type 1 diabetes trial
- Partnership deal

NTTDS
- Phase I trial in cancer pain NP2
- Co-operation with other companies
- File IND for first GAD indication NP3
- Outlicense glioma project

Other
- Neurologix - Phase II with GAD in Parkinson's

2009

Diamyd®
- Phase III - last patient in
- TrialNet intervention trial - last patient in
- LADA confirmation study
- Apply for Licence sales
- Set market strategy

NTTDS
- Phase I trial NP2 final
- Start Phase II NP2
- Phase I trial with NP3 start
- License agreement with other companies

2010

Diamyd®
- Results Phase III trials
- Filing for market approval
- Add more indications

NTTDS
- Phase II/III NP2
- Phase II NP3
- Partnership deal

DIAMYD MEDICAL

Investment Strategy

Selling 10% of shares plus additionally 10% in options will give Diamyd a possibility to

- *Run full speed with Phase III studies*
- *Continue partnership discussions as a Phase III company*



DIAMYD MEDICAL

Disclaimer

Neither the Depositary nor the Company nor any of their respective directors, supervisory or management board members, employees, agents or affiliates shall incur any liability to any Owner or Beneficial Owner of any Receipt, (i) if by reason of any provision of any present or future law or regulation of the United States or any other country, or of any other governmental or regulatory authority, or by reason of any provision, present or future, of the Stung (Articles of Association) of the Company, or by reason of any provision of any securities issued or distributed by the Company, or any offering or distribution thereof, or by reason of any act of God or war or terrorism or other circumstances beyond its control, the Depositary or the Company shall be prevented, delayed or forbidden from or be subject to any civil or criminal penalty on account of doing or performing any act or thing which by the terms of the Deposit Agreement or Deposited Securities it is provided shall be done or performed, (ii) by reason of any non-performance or delay, caused as aforesaid, in the performance of any act or thing which by the terms of the Deposit Agreement it is provided shall or may be done or performed, (iii) by reason of any exercise of, or failure to exercise, any discretion provided for in the Deposit Agreement, (iv) for the inability of any Owner or holder to benefit from any distribution, offering, right or other benefit which is made available to holders of Deposited Securities but is not, under the terms of the Deposit Agreement, made available to Owners or holders, or (v) for any special, consequential or punitive damages for any breach of the terms of the Deposit Agreement. Where, by the terms of a distribution pursuant to Section 4.01, 4.02, or 4.03 of the Deposit Agreement, or an offering or distribution pursuant to Section 4.04 of the Deposit Agreement, or for any other reason, such distribution or offering may not be made available to Owners, and the Depositary may not dispose of such distribution or offering on behalf of such Owners and make the net proceeds available to such Owners, then the Depositary shall not make such distribution or offering, and shall allow any rights, if applicable, to lapse. Where, by the terms of a distribution pursuant to Section 4.01, 4.02 or 4.03 of the Deposit Agreement, or an offering or distribution pursuant to Section 4.04 of the Deposit Agreement, such distribution or offering may not be made available to Owners of Receipts, and the Depositary may not dispose of such distribution or offering on behalf of such Owners and make the net proceeds available to such Owners, then the Depositary shall not make such distribution or offering, and shall allow any rights, if applicable, to lapse. Neither the Company nor the Depositary assumes any obligation or shall be subject to any liability under the Deposit Agreement to Owners or Beneficial Owners of Receipts, except that they agree to perform their obligations specifically set forth in the Deposit Agreement without negligence or bad faith. The Depositary shall not be subject to any liability with respect to the validity or worth of the Deposited Securities. Neither the Depositary nor the Company shall be under any obligation to appear in, prosecute or defend any action, suit, or other proceeding in respect of any Deposited Securities or in respect of the Receipts on behalf of any Owner or holder. Neither the Depositary nor the Company shall be liable for any action or non action by it in reliance upon the advice of or information from legal counsel, accountants, any person presenting Shares for deposit, any Owner or Beneficial Owner of a Receipt, or any other person believed by it in good faith to be competent to give such advice or information. The Depositary shall not be responsible for any failure to carry out any instructions to vote any of the Deposited Securities, for any failure to timely receive a Recommendation, for the manner in which any such vote is cast, or for the effect of any such vote, including, without limitation, any deemed proxy or proxy in connection with a Recommendation or any failure to vote in accordance with a Recommendation, provided that any such action or non action is in good faith. The Depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the Depositary or in connection with a matter arising wholly after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises, the Depositary performed its obligations without negligence or bad faith while it acted as Depositary.